http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102391494-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 |
| filingDate | 2014-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102391494-B1 |
| titleOfInvention | Liquid formulation with enhanced stability comprising montelukast or pharmaceutically acceptable salt thereof and method for preparing same |
| abstract | The present invention relates to a liquid formulation comprising montelukast or a pharmaceutically acceptable salt thereof as an electrolyte compound and an active ingredient, and a method for preparing the same. According to the present invention, montelukast or a pharmaceutically acceptable salt thereof is substantially dissolved therein. Because it exists in a solution state, there is no degradation of stability and dissolution with time, and bioavailability can be increased. In addition, the liquid formulation of the present invention has excellent stability, taste and aroma, and thus can improve patients' medication compliance, and thus can be usefully used in the treatment of patients such as asthma and allergic rhinitis. |
| priorityDate | 2014-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.